Convatec completes over £24 million expansion of UK manufacturing site, strengthening supply of advanced wound care solutions

• Multi-year investment of over £24 million completed in Rhymney, South Wales, expanding production capacity for Convatec's flagship Hydrofiber^® Technology wound care dressing material
•  Almost 1.5 billion Aquacel^® dressings have been sold worldwide leveraging Hydrofiber^® Technology over the last three decades, as the technology celebrates its 30^th anniversary this year
• Investment reinforces Convatec's commitment to UK life sciences manufacturing, following its previously announced £500 million UK R&D investment plans over the next decade

London, UK, 3 July 2026 – Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, today announces the completion of a multi-year expansion of over £24 million at its manufacturing site in Rhymney, South Wales. A new production line, inaugurated today with a ribbon-cutting ceremony, will strengthen Convatec’s industry-leading Advanced Wound Care innovation pipeline.

The investment builds on nearly four decades of expertise at the Rhymney site, supporting highly skilled manufacturing in the region and reinforcing its role as a centre of excellence for Hydrofiber^® Technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation and helps manage the burden of wound care. Used in advanced wound care solutions, this technology helps clinicians manage complex wounds and improve patient outcomes. Almost 1.5 billion Aquacel^® dressings have been sold worldwide leveraging the technology over the last three decades.

The expansion also reflects Convatec's ongoing commitment to the UK life sciences sector. Across its UK sites, including manufacturing in Deeside and Rhymney, the company continues to invest in the skills, infrastructure and innovation needed to support patients living with chronic conditions around the world. 

The UK plays a central role in the company's global manufacturing network, producing Advanced Wound Care products that are exported to approximately 90 countries worldwide. Convatec employs approximately 650 colleagues across its UK manufacturing operations. Around 15% are based at the expanded site in South Wales, with the remainder operating out of Convatec’s larger manufacturing site in Deeside. Last October, Convatec announced plans to invest more than £500 million in UK R&D, including establishing a new state-of-the-art R&D hub in Manchester in 2028.

Tanja Dormels, President, Advanced Wound Care at Convatec, said: "For nearly four decades, our Rhymney team has built deep expertise and world-class manufacturing capability, and this expansion is a testament to their skill, dedication and pride in serving patients. By strengthening production in the UK, we can reach more people around the world with trusted wound care solutions, while keeping that expertise firmly rooted in Rhymney and the wider UK life sciences ecosystem.”

Nick Smith, MP for Blaenau Gwent and Rhymney, said: "The completion of Convatec’s multi-year investment of over £24 million is a significant vote of confidence in UK and Welsh manufacturing and in the talented people who work at this site. Convatec is one of many firms supporting a stronger future for the life sciences sector in Wales, which in turn is benefiting patients across the UK. I was delighted to be here to mark this milestone with the team."

The Rhymney site has operated as a manufacturing hub since 1986. Its approximately 100 colleagues produce more than 350 metric tonnes of Hydrofiber^® annually, a soft, absorbent material that transforms into a gel on contact with wound fluid, creating an optimal healing environment. It is a core component of products including Aquacel^® Extra™, Aquacel^® Ag Foam, ConvaFoam™, and Aquacel™ ConvaFiber™, which are used in hospitals and care settings across the UK and globally.

Notes to editors

UK market environment
It is vital that companies like Convatec can continue to invest in pioneering medical solutions in the UK. Convatec sees the UK as an attractive destination for life sciences, with a deep talent pool, strong research base, and supportive environment for innovation. Convatec’s plans, subject to government support, reflect our confidence in the UK’s future as a global hub and in the role Convatec can play in delivering solutions to our customers. It is critical that UK Government policy, legislation, reimbursement decisions and initiatives enable companies like Convatec, with UK manufacturing, R&D and other investments in the UK, to serve the best interests of patients, protect patient and provider choice, and deliver value for taxpayers.

Contacts
Media: mediarelations@convatec.com 
Investor Relations: IR@convatec.com 

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and treatment for hard-to-heal wounds, at-risk skin and ulcerated tissue, to supporting debilitating conditions, improving patient outcomes and reducing care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com